BioSpace News Archive

Vireo Health International, Inc. (“Vireo” or the “Company”) (CNSX: VREO; OTCQX: VREOF), a leading science-focused, multi-state cannabis company, today announced that its shares have received Depository Trust Company (DTC) full-service eligibility in the United States.

The Critical Path Institute (C-Path) and the National Organization for Rare Disorders® (NORD) launched the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP) in Rockville, MD on Tuesday, Sept. 17

Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the appointment of Patrick Gray to the Dicerna board of directors (the “board”) as an independent director, and the retirement of veteran director Dennis Langer, M.D., J.D. Mr. Gray will serve as the chairperson of the Audit Committee.

The world-class surgeons at Eyesthetica have been featured in Pasadena Magazine, honored among the top health practitioners of 2019.

Biocom, the association representing the life science industry of California, issued the following statement in response to a drug pricing proposal unveiled by Speaker Nancy Pelosi and sponsored by Energy & Commerce Chairman Frank Pallone – H.R.3, the Lower Drug Costs Now Act – in the U.S. House of Representatives today.

Just ahead of World Alzheimer’s Day on September 21st, Tetra Therapeutics, a clinical-stage biotechnology company, today announced it has surpassed 50% enrollment – 65% of which are Hispanic patients– in its Phase 2 clinical trial (PICASSO AD) of BPN14770 in patients diagnosed with early Alzheimer’s disease (AD), since the trial’s initiation in May.

This is the second of a two part series exploring wearable medical devices.

The National Coalition on Health Care, the nation’s oldest and broadest based stakeholder coalition, welcomes the introduction of a comprehensive bill to address out of control drug prices by Speaker Pelosi today.

Context Therapeutics, a clinical-stage biopharmaceutical company dedicated to advancing medicines for hormone driven cancers, today announced a Phase 2 clinical collaboration with the Sidney Kimmel Cancer Center at Jefferson Health.

Pharma Property Group recorded nine sales over a 45-day period with a total of approximately $43,350,000.